This is a multicenter clinical trial, phase III, non-inferiority, controlled by active medicine, open, randomized, enroll 538 children, 2 to 12 years old, with acute inflammation upper airway, characterized by nasal congestion and runny nose, lasting at least 24 hours and a maximum of 48 hours prior to inclusion. The subjects will be allocated in 2 parallel groups, and will receive the medicines of study, according of the randomization.

Clinical score of upper airway compromise [ Time Frame: After 2 and 5 (± 1) days of treatment ] [ Designated as safety issue: No ]

Proportion of subjects who used at least once the rescue medication [ Time Frame: Within 2 days and the period of 5 (± 1) days of treatment ] [ Designated as safety issue: No ]

Safety descriptive about occurence of adverse events, evaluation of results of general physical examination. [ Time Frame: Will be evaluated during the 5(± 1) days of treatment ] [ Designated as safety issue: Yes ]

Patients between 2 and 12 years old, of both sexes. Must be responsible be able to understand and provide ICF and able to allow compliance to treatment and protocol requirements, fulfilling the regular visits;

Patients with symptoms of acute inflammation upper airway, starting between 24 and 48 hours of their inclusion in this study protocol;

Presence of runny nose classification moderate or severe (score 2 or 3), according the responsible evaluation;

Presence of nasal congestion classification moderate or severe (score 2 or 3), according the responsible evaluation.

Exclusion Criteria:

Patients younger than 2 years or percentile for body weight and/or height less than 25;

History of nasal obstruction in chronic rhinosinusitis and / or nasal polyposis;

Oral chronic respirator with history for six months;

Personal history of nasal surgery that in the opinion of the investigator can influence the resistance to nasal airflow;

Patients who have a clinical history confirmed (diagnosed) with asthma;

Patients under medicine treatment for chronic allergy;

Patients with gastroesophageal reflux disease;

Presence of psychiatric illness of any kind;

Presence of mental retardation from any cause;

Diagnosis of renal or hepatic failure;

Patients with genetic syndromes;

History of hypersensitivity to (s) drug (s) of study or their excipients;

Use of prohibited medicine within the prescribed period before the V0 - Inclusion Visit (Table 1);

Patients who participated in the last 12 months, of clinical trials protocols;

Patients who didn´t updated vaccine book;

Relatives of sponsor´s or study site´s employee;

Suggestive signs of bacterial infection of upper airways at rhinoscopy, otoscopy or oroscopy;

Presence of anemic/inflamed turbinate at anterior rhinoscopy;

Presence of septal deviation grade II and III (in any region and any nasal cavity) and / or nasal polyps, or other conditions determinants of nasal obstruction;

Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01393548